This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study


Glasser, Stephen P., Wadley, Virginia, Judd, Suzanne, Kana, Bhumika, Prince, Valerie, Jenny, Nancy, Kissela, Brett, Safford, Monika, Prineas, Ronald, Howard, George


Clinical Cardiology, Volume: 33, No.: 5, Pages.: 280-288

Year of Publication



Background: Statin use and type have been variably associated with impaired or improved cognitive performance.; Hypothesis: To assess the association of statin use and type (lipophilic vs hydrophilic) and cognitive impairment.; Methods: Cross-sectional analysis of 24 595 participants (7191 statin users and 17 404 nonusers) age > or = 45 years, from a population-based national cohort study (Reasons for Geographic And Racial Differences in Stroke) enrolled between January 2003 and October 2008, with oversampling from the southeastern Stroke Belt and African Americans. Statin use and type were documented in participants’ homes by a trained health professional. Cognitive performance was assessed with a prior validated instrument of global cognitive status (Six-Item Screener). Cognitive impairment was defined as a score of < 4.; Results: Overall, an association of cognitive impairment and statin use was observed (8.6% of users vs 7.7% of nonusers had cognitive impairment, P = 0.014); but, after adjusting for variables known to be associated with cognition (age, gender, race, income, education level, and cardiovascular disease), the association was attenuated (odds ratio [OR]: 0.98, confidence interval [CI]: 0.87-1.10). No association was observed between statin type (lipophilic vs hydrophilic) and cognition (OR: 1.03, CI: 0.86-1.24), and there were no regional differences in cognitive impairment in statin users (8% in the Stroke Belt and 7.9% in other regions, P = 0.63).; Conclusions: Statin use and type were marginally associated with cognitive impairment. After adjusting for known variables that affect cognition, no association was observed. No regional differences were observed. This large study found no evidence to support an association between statins and cognitive performance.; Copyright 2010 Wiley Periodicals, Inc.

Bibtex Citation

@article{Glasser_2010, doi = {10.1002/clc.20758}, url = {}, year = 2010, month = {may}, publisher = {Wiley-Blackwell}, volume = {33}, number = {5}, pages = {280--288}, author = {Stephen P. Glasser and Virginia Wadley and Suzanne Judd and Bhumika Kana and Valerie Prince and Nancy Jenny and Brett Kissela and Monika Safford and Ronald Prineas and George Howard}, title = {The Association of Statin Use and Statin Type and Cognitive Performance: Analysis of the Reasons for Geographic and Racial Differences in Stroke ({REGARDS}) Study}, journal = {Clin Cardiol} }


adult, adverse effects, african americans, aged, aged, 80 and over, cognition, cognition disorders, databases as topic, diagnosis, drug effects, epidemiology, ethnology, european continental ancestry group, female, humans, logistic models, male, middle aged, odds ratio, psychiatric status rating scales, psychology, residence characteristics, risk assessment, risk factors, statin, stroke, therapeutic use, united states, users

Countries of Study


Types of Study

Cohort Study

Type of Outcomes


Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population